CTCs from the primary tumor and tumor core are fused into blood vessels either directly or via EMT. Activation of macrophages (MΦ*) enhances extracellular matrix lysis and neovascularization by matrix metalloproteinase-9 and blood vessel endothelial growth factor, respectively. The circulation of CTCs can be single intact or apoptotic CTCs, or small clusters of cells. Extravasion of the CTCs is supported by local recruitment of macrophages (MΦ*) which may then release a second wave after the formation of new blood vessels. Then the invading cells may grow into metastasis.

SRY-box transcription factor 30 (SOX30) has been widely reported to potentially affect cancer. In this study, we conducted several bioinformatics analyses based on open databases and reviewed articles that provide evidence for the impact of SOX30 on cancer. Specifically, our research aimed to (1) provide an overview of SOX30 in cancer; (2) summarize the evidence of SOX30's effects on cancer; and (3) identify new research pathways for SOX30's role in cancer.

Treatment-induced cardiovascular toxicity is linked to ADT, VEGFR-TKIs, ICIs, and chemotherapy. We propose the new discipline of uro-cardio-oncology to address the relationship between cardiovascular disease and urological cancers. ADT, androgen deprivation therapy; ICI, immune checkpoint inhibitor; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitor.

With crucial mutational categories, biosimilar drug prototypes, and clinical practices including blood and liquid biopsy, cell therapy, gene therapy, recombinant therapeutic proteins, and tailored pharmaceuticals, it aids in targeting certain organs. Monoclonal drugs commonly used in cancer therapy include monoclonal antibodies like trastuzumab, rituximab, infliximab, and epoetin.

Mechanisms of therapeutic strategies for von Hippel-Lindau (VHL) disease are discussed. Sorafenib and tislelizumab exhibited the ability of anti-VHL disease by targeting mutation of VHL-induced oncogenes expression including vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and blocking PD-1/PD-L1 pathway.

We reported a rare case of paratesticular alveolar rhabdomyosarcoma (RMS) with multiple metastases in a 16-year-old boy and its findings on ¹⁸F-fluoro-deoxyglucose (¹⁸F-FDG) positron emission tomography (PET)/computed tomography (CT). This case indicates the potential value of ¹⁸F-FDG PET/CT in rhabdomyosarcoma staging and therapy decisions and may assist in the differential diagnosis.

A case-control study was conducted in 402 neuroblastoma patients and 473 controls in Nanjing Children's Hospital. Genotyping was performed by Taqman method. Based on eQTL analysis and multiple logistic regression model, we found that ALKBH5 gene polymorphisms (rs1378602 and rs8400) were only weakly associated with the risk of neuroblastoma.

Histone deacetylase (HDAC) inhibitor (HDACi) is a potent antitumor drug candidate for synovial sarcoma (SS) treatment. Twist1 expression often causes drug resistance. SN38 overcomes Twist1-induced drug resistance for HDACi through the suppression of Twist1 protein expression in SS cells.